HRMY (Harmony Biosciences Holdings) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRMY Harmony Biosciences Holdings Inc HRMY
94 GF Score
Price $38.74
GF Value $46.81
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harmony Biosciences Holdings SpecialCharges?

Special Charges only applies to banks.

HRMY
94GF Score
Harmony Biosciences Holdings Inc HRMY
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?

Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued. The current stock price of $38.74 is trading 17.2% below its estimated GF Value™ of $46.81. GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.

Key valuation signals for HRMY:

  • SpecialCharges:
  • GF Value™: $46.81 vs. price of $38.74 (17.2% below fair value)
  • GF Score™: 94/100 with 2 warning signs

No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Harmony Biosciences Holdings Business Description

Address 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
94GF Score

Get the complete analysis for HRMY

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.74
Price
$46.81
GF Value